ImageneBio, Inc. (IMA) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 31.46M USD | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 17.12M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -58.96M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $31.46M | (m) | $17.12M | $-58.96M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $30.45M | (m) | $16.21M | $-54.53M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $28.52M | $800.00K | $15.39M | $-48.45M | (m) | 3565.63% | 1923.88% | (m) | (m) |
| 2025-09-30 | $27.78M | (m) | $20.64M | $-68.06M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $19.14M | (m) | $3.38M | $-44.47M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $24.95M | (m) | $4.20M | $-51.54M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $30.88M | (m) | $5.29M | $-58.97M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $40.57M | (m) | $6.05M | $-68.36M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $48.41M | (m) | $7.03M | $-75.46M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $53.74M | (m) | $7.63M | $-78.13M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $59.65M | $9.16M | $7.63M | $-75.42M | (m) | 651.22% | 83.32% | (m) | (m) |
| 2023-09-30 | $61.02M | $13.95M | $7.74M | $-68.62M | (m) | 437.37% | 55.45% | (m) | (m) |
| 2023-06-30 | $65.21M | $19.17M | $7.55M | $-67.00M | (m) | 340.22% | 39.38% | (m) | (m) |
| 2023-03-31 | $65.53M | $17.55M | $7.63M | $-69.46M | (m) | 373.45% | 43.45% | (m) | (m) |
| 2022-12-31 | $64.32M | $15.62M | $7.53M | $-70.90M | (m) | 411.84% | 48.18% | (m) | (m) |
| 2022-09-30 | $61.02M | $30.39M | $7.25M | $-53.00M | (m) | 200.82% | 23.85% | (m) | (m) |
| 2022-06-30 | $55.54M | $27.73M | $6.88M | $-49.64M | (m) | 200.31% | 24.83% | (m) | (m) |
| 2022-03-31 | $51.43M | $30.89M | $6.19M | $-41.38M | (m) | 166.47% | 20.04% | (m) | (m) |
| 2021-12-31 | $47.11M | $30.98M | $5.18M | $-34.14M | (m) | 152.03% | 16.71% | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $44.85M | $9.19M | $1.80M | $-44.52M | (m) | 487.79% | 19.55% | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |